Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Raw Materials (2024 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Raw Materials for 2 consecutive years, with $37.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Raw Materials rose 581.14% to $37.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $37.9 million, a 581.14% increase, with the full-year FY2024 number at $27.7 million, changed N/A from a year prior.
  • Raw Materials was $37.9 million for Q1 2025 at Iovance Biotherapeutics, up from $27.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $37.9 million in Q1 2025 to a low of $5.6 million in Q1 2024.